TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals announced its total issued share capital consists of 4,343,539 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to determine their investment status under the Financial Conduct Authority’s rules, impacting how they manage their interests in the company’s share capital.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several product candidates and platform technologies.
Average Trading Volume: 40,789
Technical Sentiment Signal: Sell
Current Market Cap: £7.71M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.